Nicholas A Peppas
Overview
Explore the profile of Nicholas A Peppas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
227
Citations
9793
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wagner A, Lanier O, Savk A, Peppas N
RSC Pharm
. 2025 Feb;
PMID: 39990011
Ovarian cancer is one of the leading causes of cancer-related deaths in women, with limited progress in treatments despite decades of research. Common treatment protocols rely on surgical removal of...
2.
Roy A, Afshari R, Jain S, Zheng Y, Lin M, Zenkar S, et al.
Chem Soc Rev
. 2025 Feb;
54(5):2595-2652.
PMID: 39927792
Recent advancements in wearable biosensors and bioelectronics have led to innovative designs for personalized health management devices, with biocompatible conducting nanocomposite hydrogels emerging as a promising building block for soft...
3.
Lei L, Song Y, Yang L, Wang Y, Xia X, Zhang Y, et al.
Proc Natl Acad Sci U S A
. 2025 Jan;
122(5):e2416796122.
PMID: 39874295
Carrier-free nanomedicines exhibited significant potential in elevating drug efficacy and safety for tumor management, yet their self assembly typically relied on chemical modifications of drugs or the incorporation of surfactants,...
4.
Soukar J, Peppas N, Gaharwar A
Adv Sci (Weinh)
. 2025 Jan;
12(7):e2411720.
PMID: 39806939
Organelles are specialized subunits within cells which carry out vital functions crucial to cellular survival and form a tightly regulated network. Dysfunctions in any of these organelles are linked to...
5.
Cisneros E, Morse B, Savk A, Malik K, Peppas N, Lanier O
J Nanobiotechnology
. 2024 Nov;
22(1):714.
PMID: 39548452
Despite their potential, the adoption of nanotechnology in therapeutics remains limited, with only around eighty nanomedicines approved in the past 30 years. This disparity is partly due to the "one-size-fits-all"...
6.
Ramirez-Velez I, Namjoshi A, Effiong U, Peppas N, Belardi B
ACS Nano
. 2024 Aug;
18(32):21038-21051.
PMID: 39096293
A general platform for the safe and effective oral delivery of biologics would revolutionize the administration of protein-based drugs, improving access for patients and lowering the financial burden on the...
7.
Lanier O, DAndrea A, Shodeinde A, Peppas N
J Appl Polym Sci
. 2024 Jul;
141(9).
PMID: 38962028
In this study, we use modified cationic nanocarriers as vehicles for the intracellular delivery of therapeutic siRNA. After developing nanocarrier formulations with appropriate pK, size, swellability, and cytocompatibility, we investigated...
8.
Wang Y, Yang L, Yan C, Du Y, Li T, Yang W, et al.
Sci Adv
. 2024 Jun;
10(25):eadn8079.
PMID: 38905336
Autophagy-targeting chimera (AUTAC) has emerged as a powerful modality that can selectively degrade tumor-related pathogenic proteins, but its low bioavailability and nonspecific distribution significantly restrict their therapeutic efficacy. Inspired by...
9.
Clegg J, Sun J, Gu J, Venkataraman A, Peppas N
J Control Release
. 2024 Jun;
371:619-620.
PMID: 38890014
No abstract available.
10.
Near-infrared light-responsive hydrogels for on-demand dual delivery of proangiogenic growth factors
Nazemidashtarjandi S, Larsen B, Cheng K, Faulkner S, Peppas N, Parekh S, et al.
Acta Biomater
. 2024 Jun;
183:61-73.
PMID: 38838911
Achieving precise spatiotemporal control over the release of proangiogenic factors is crucial for vasculogenesis, the process of de novo blood vessel formation. Although various strategies have been explored, there is...